{
    "clinical_study": {
        "@rank": "163241", 
        "acronym": "EXIT - V", 
        "arm_group": [
            {
                "arm_group_label": "Exercise training", 
                "arm_group_type": "Experimental", 
                "description": "Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute.  Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks."
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "No Intervention", 
                "description": "Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction."
            }
        ], 
        "brief_summary": {
            "textblock": "Patients who have suffered a heart attack are at risk of developing worsening heart function\n      and heart failure.  Exercise training has a beneficial effect on heart function and prevents\n      heart failure.  The aim of the current study is to investigate the effect of exercise\n      training on heart function in patients who have suffered a heart attack."
        }, 
        "brief_title": "Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Myocardial Infarction", 
            "Heart Failure", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Failure", 
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who have suffered a myocardial infarction are at significant risk for developing\n      heart failure and progressive left ventricular dysfunction  One of the proposed mechanisms\n      responsible for this observation is reduction in myocardial beta-adrenergic receptor density\n      due to elevated cell membrane protein G - protein coupled receptor kinase -2 (GRK2).\n\n      It is known that exercise training preserves heart function in patients who have suffered a\n      myocardial infarction.  The mechanism for this is not clear.\n\n      The purpose of this study is to examine the effect of exercise training on myocardial\n      function and GRK2 levels in patients who have suffered a myocardial infarction, with the\n      hypothesis that exercise training in this population reduces GRK2 levels and preserves or\n      improves myocardial function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Acute myocardial infarction\n\n          -  Complete revascularization: no residual major epicardial coronary artery coronary\n             stenosis \u2265 70%; no residual left main coronary stenosis \u2265 40%.\n\n          -  Stage A-C heart failure, New York Heart Association class I-III.\n\n          -  Stable dose of medications during the 4 weeks prior to enrolment.\n\n          -  Able to perform a maximal cardiopulmonary stress test.\n\n          -  Capacity and willingness to provide sign informed consent.\n\n        Exclusion Criteria:\n\n          -  Pregnant\n\n          -  Coronary artery bypass surgery: patients post coronary artery bypass graft exhibit\n             wall motion abnormalities that may interfere with speckle tracking analysis.\n\n          -  Incomplete revascularization with major epicardial coronary artery (left anterior\n             descending, circumflex, or right coronary) stenosis \u2265 70%.\n\n          -  Myocardial necrosis in the absence of significant flow limiting coronary artery\n             stenosis or thrombosis, with the exception of documented STEMI and successful\n             thrombolytic therapy resulting on no significant residual epicardial coronary artery\n             stenosis.\n\n          -  Significant valvular disease that is greater than moderate in severity\n\n          -  History of non-ischemic cardiomyopathy (dilated, restrictive, infiltrative\n             cardiomyopathy, hypertrophic, LV non compaction, or Takotsubo cardiomyopathy)\n\n          -  Significant resting ECG abnormalities that preclude accurate speckle tracking.\n\n          -  Paced rhythm.\n\n          -  left bundle branch block\n\n          -  Atrial arrhythmias (ex. persistent/permanent atrial fibrillation, atrial flutter).\n\n          -  Frequent ventricular ectopics\n\n          -  Significant ventricular arrhythmias (non-sustained ventricular tachycardia or\n             syncope).\n\n          -  New York Heart Association class IIIb - IV symptoms.\n\n          -  Severe LV systolic dysfunction (Ejection fraction \u2264 30%)\n\n          -  Active decompensated heart failure with orthopnea or paroxysmal nocturnal dyspnea.\n\n          -  Uncontrolled resting arterial hypertension > 180/110 mmHg.\n\n          -  More than moderate systemic disease\n\n          -  Chronic inflammation or infection.\n\n          -  Any contraindication to exercise training or any condition limiting ability to\n             partake in adequate exercise stress testing or training (peripheral artery disease,\n             articular, neurologic, or psychiatric pathology)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048696", 
            "org_study_id": "13-1509"
        }, 
        "intervention": {
            "arm_group_label": "Exercise training", 
            "intervention_name": "Secondary prevention and cardiac rehabilitation clinic", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Exercise training", 
            "High intensity interval training", 
            "left ventricular systolic function", 
            "G-protein related kinase 2", 
            "heart failure", 
            "myocardial infarction", 
            "coronary artery disease", 
            "beta adrenergic receptor"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "contact": {
                "last_name": "Julie Lalong\u00e9, RT"
            }, 
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H1T 1N6"
                }, 
                "name": "Centre for preventive medicine and physical activity of the Montreal Heart Institute (Centre \u00c9PIC)"
            }, 
            "investigator": [
                {
                    "last_name": "Douglas A Hayami, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Martin Juneau, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction: The EXercise Interval Training - V Study", 
        "other_outcome": [
            {
                "description": "change in fasting glucose", 
                "measure": "Fasting glucose", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change in serum lipids", 
                "measure": "serum lipids", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }
        ], 
        "overall_contact": {
            "email": "julie.lalonge@icm-mhi.org", 
            "last_name": "Julie Lalong\u00e9, RT", 
            "phone": "514-374-1480", 
            "phone_ext": "259"
        }, 
        "overall_contact_backup": {
            "email": "anil.nigam@icm-mhi.org", 
            "last_name": "Anil Nigam, MD", 
            "phone": "514-376-3330", 
            "phone_ext": "4033"
        }, 
        "overall_official": {
            "affiliation": "Montreal Heart Institute", 
            "last_name": "Anil Nigam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "change in lymphocyte GRK2 mRNA levels", 
            "measure": "Lymphocyte GRK2 mRNA level", 
            "safety_issue": "No", 
            "time_frame": "at baseline and following 12 weeks exercise training intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048696"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "change in left ventricular systolic function", 
                "measure": "Left ventricular systolic function", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "Change in left ventricular dimensions", 
                "measure": "Left ventricular dimensions", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change in plasma epinephrine", 
                "measure": "Plasma epinephrine", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change change in autonomic tone", 
                "measure": "heart rate variability", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "Change before and after exercise training", 
                "measure": "exercise capacity (VO2max)", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "Change in awake and 24h blood pressure", 
                "measure": "ambulatory blood pressure", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change in plasma brain naturietic peptide", 
                "measure": "Plasma brain natriuretic peptide", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change in maximal cardiac output and stroke volume", 
                "measure": "Maximal cardiac output and stroke volume using electrical bioimpedance", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }, 
            {
                "description": "change in lymphocyte GRK2 protein levels", 
                "measure": "lymphocyte GRK2 protein levels", 
                "safety_issue": "No", 
                "time_frame": "at baseline and following 12 weeks exercise training intervention"
            }
        ], 
        "source": "Montreal Heart Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Montreal Heart Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}